First-line treatment for ovarian cancer! Roche Tecentriq s/Avastin-Chemotherapy Program Phase III Clinical: Failure to Extend Progressless Survival!

!--:pagetitle"--/ -- Roche has announced the latest advances in the anti-PD-L1 therapy Tecentriq (Tesanchi, generic name: atezolizumab, atlizumad) first-line treatment for newly diagnosed women with advanced ovarian cancerresults showed that the addition of Tecentriq to Avastin (avetin, generic name: bevacizumab, befalsazumab) and the combination of yew alcohol and kapurn failed to reach the main end point of improving progression-free survival (PFS)IMagyn050 is a multi-center, random, double-blind Phase III study conducted in patients with Stage III or Iv ovarian cancer who are receiving new auxiliary or assisted therapy, to evaluate the efficacy and safety of Tecentriq-Avastin-Suppur-carpur-combination drug regimen and Avastin-suprapur-kapur combination drug regimenstudy, patients were randomly grouped in a 1:1 ratio before or after a tumor ectomy (new assistance) or postoperative (auxiliary)common primary endpoints are: intentional therapy (ITT) and PD-L1-positive subgroups, progression-free survival (PFS) and total survival (OS) determined by the study investigatorsKey secondary endpointsinclude: objective remission rate (ORR), safety, tolerance, patient-reported abdominal pain, and improvements in bloatingthe study is being conducted by Roche in collaboration with the GOG Foundation (GOG-3015) and the European Network of Gynaecological Oncology TestIng Group (ENGOT) (ENGOT OV-39)released data showed that tecentriq plus avastin-carpur combined drug regimen did not improve progression-free survival (PFS) compared to the Avastin-serosin-carpur-combined drug regimenthe study, tecentriq combined avastin, yew alcohol, and carpurin to be consistent with known combination drug safetycurrently, the study's common primary endpoint, OS data, is premature, and follow-up will continue until the next planned analysisthe results of theIMagyn050 study will be further evaluated to inform the Tecntriq Gynaecology Development ProjectThe Tecentriq Ovarian and Cervical Cancer Project, based on a joint application of Tecentriq and Avastin, helps newly diagnosed, advanced or recurrent ovarian and cervical cancer women survive longer without worsening the disease, a result demonstrated in seven key Phase III trials involving more than 5,000 womenRoche has developed a wide range of development programs for Tecentriq, including a number of ongoing and planned phase III studies of lung, urinary, skin, breast cancer, gastrointestinal cancer, gynaecological and head and neck cancers, including the evaluation of Tecentriq monodrug therapy or combination with other drugs"Ovarian cancer remains one of the most aggressive cancers and is difficult to treat in the advanced stages," said DrLevi Garraway, chief medical officer and global product development officer at Roche but we remain committed to improving the prognosis of these female patients and are pleased that Avastin remains a key component of the first-line ovarian cancer treatment regimen " ovarian cancer is the eighth most common female cancer in the world, with nearly 300,000 new diagnoses each year ovarian cancer remains the leading cause of death from malignant tumors in women, as most patients are not diagnosed with advanced disease until they have a terminal illness, and the five-year survival rate is less than 30% Tecentriq is a PD-(L) 1 tumor immunotherapy that targets the PD-L1 protein expressed on tumor cells and tumor-immersed immune cells, blocking its interaction with PD-1 and B7.1 receptors by inhibiting PD-L1, Tecentriq can activate T cells to date, Tecentriq has been approved by several countries as monodrug therapy and combination of targeted therapy and/or chemotherapy for a variety of types of cancer, including: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), certain types of metastatic urinary tract skin cancer (mUC), PD-L1-positive triple-negative breast cancer (TNBC), etc Avastin is an angiogenesis inhibitor that targets the endothelial growth factor (VEGF) VEGF plays an important role in angiogenesis and maintenance during the life cycle of tumors Avastin infects the tumor's blood supply by binding directly to VEGF, preventing it from interacting with receptors on vascular cells The blood supply to tumor is considered to be the key to the tumor's ability to grow and transfer in the body combining Tecentriq with Avastin has a strong scientific basis, and the Tecentriq-Avastin combination has the potential to strengthen the immune system against tumors In addition to its established anti-angiogenesis, Avastin can further enhance Tericentq's ability to restore the body's anti-cancer immunity by inhibiting VEGF-related immunosuppression, promoting T-cell tumor immersion, and initiating T-cell response to tumor antigens in the United States, the FDA approved in December 2018 for the first line of treatment for metastatic non-scaly non-small cell lung cancer (NSq NSCLC) patients without EGFR or ALK genomic tumor distortion the approved Group B patient data based on the IMpower150 study: In patients with intentional treatment wild type (ITT-WT), Tecentriq-Avastin-chemotherapy significantly extended the patient's survival (median OS: 19.2 months vs 14.7 months, HR 0.78, p.016) compared to Avastin-chemotherapy at the end of May this year, the FDA approved Tecentriq-Avastin for the treatment of patients with non-removable or metastatic hepatocellular carcinoma (HCC) who had not previously been treated with a systematic system noteworthy, the Tecentriq-Avastin portfolio is the first and only approved cancer immunotherapy program for the treatment of non-removable or metastatic HCC data from the IMbrave150 clinical trial showed that the Tecentriq-Avastin combination therapy significantly extended total survival (OS) and progression-free survival (PFS) compared to the standard care drug sorafenib (!--/ewebeditor:!--webeditor: !--webeditor: page title""----s original source: Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer !--/ewebeditor:page."